Tranexamic acid

Status
Phase 2
Condition
COVID-19
Intervention Type
Oral Drug
Funder Type
Organization | University

Drug Details

Tranexamic acid is a synthetic derivative of the amino acid lysine that exerts its antifibrinolytic effect through the reversible blockade of lysine binding sites on plasminogen molecules.

Study Purpose

Controlled trials of the drug tranexamic acid (TXA) in inpatients recently admitted to the hospital and outpatients with the diagnosis of COVID19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >